SCHEMBL608754

SCHEMBL608754

O=C(O)c1cc(NCCc2ccccc2)ccc1O

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOX4 Q9NPH5 2/20 0.61
MCL1 Q07820 1/20 0.61
BCL2A1 Q16548 1/20 0.61
SYK P43405 2/20 0.57
KDM4C Q9H3R0 2/20 0.56
PPARA Q07869 1/20 0.56
STING1 Q86WV6 1/20 0.56
HNF4A P41235 1/20 0.54
ALDH1A1 P00352 2/20 0.54
EGFR P00533 2/20 0.54
MAPT P10636 2/20 0.54
RGS12 O14924 1/20 0.54
LCK P06239 1/20 0.54
CAMKK2 Q96RR4 1/20 0.54
TDP1 Q9NUW8 1/20 0.54
PTPN1 P18031 1/20 0.51
KDM4E B2RXH2 2/20 0.50
ASPH Q12797 1/20 0.50
RIOX2 Q8IUF8 1/20 0.50
KDM8 Q8N371 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL610427 0.91 SYK (0.59) NOX4MCL1BCL2A1SYKKDM4C
SCHEMBL4095116 0.90 NOX4 (0.57) NOX4MCL1BCL2A1SYKKDM4C
SCHEMBL610123 0.87 SYK (0.58) NOX4MCL1BCL2A1SYKKDM4C
SCHEMBL4095004 0.87 KDM4C (0.56) NOX4MCL1BCL2A1SYKKDM4C
SCHEMBL29388077 0.87 SYK (0.58) NOX4MCL1BCL2A1SYKKDM4C
SCHEMBL4098010 0.86 NOX4 (0.50) NOX4MCL1BCL2A1SYKKDM4C
SCHEMBL608498 0.85 KDM4C (0.53) NOX4MCL1BCL2A1SYKKDM4C
SCHEMBL611490 0.84 KDM4C (0.76) NOX4SYKKDM4CPPARASTING1
SCHEMBL29532272 0.84 KDM4C (0.76) NOX4SYKKDM4CPPARASTING1
SCHEMBL29390970 0.84 CNR1 (0.52) NOX4MCL1BCL2A1KDM4CPPARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3902536-B1 COMPOSITIONS COMPRISING 5-BENZYLAMINOSALICYLIC ACID COMPOUNDS FOR USE IN TREATING NEURODEGENERATIVE DISORDERS IN A COMPANION ANIMAL GNT PHARMA CO LTD (KR) 2025-09-03 EP claimed
EP-4456890-A2 COMPOSITIONS AND METHODS FOR TREATING PULMONARY DISORDERS GNT Pharma Co., Ltd (KR) 2024-11-06 EP claimed
WO-2023156808-A2 COMPOSITIONS AND METHODS FOR TREATING PULMONARY DISORDERS GNT PHARMA CO., LTD. (KR) 2023-08-24 WO claimed
US-20230233503-A1 COMPOSITIONS AND METHODS FOR TREATING PULMONARY DISORDERS GNT PHARMA CO., LTD. (KR) 2023-07-27 US claimed
US-20220241231-A1 COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISORDERS GNT PHARMA CO., LTD. (KR) 2022-08-04 US claimed
CN-113710242-A Compositions and methods for treating neurodegenerative disorders 吉恩特药业株式会社 2021-11-26 CN claimed
EP-3902536-A1 COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISORDERS GNT Pharma Co., Ltd (KR) 2021-11-03 EP claimed
US-20200206172-A1 COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISORDERS GNT PHARMA CO., LTD. (KR) 2020-07-02 US claimed
WO-2020136441-A1 COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISORDERS GNT PHARMA CO., LTD. (KR) 2020-07-02 WO claimed
EP-2004164-B1 PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING INFLAMMATORY DISEASES NEUROTECH PHARMACEUTICALS CO LTD (KR) 2018-08-08 EP claimed
US-20130316988-A1 Pharmaceutical Composition for Treating or Preventing Degenerative and Inflammatory Diseases NEUROTECH PHARMACEUTICALS CO., LTD. (KR) 2013-11-28 US claimed
US-8455470-B2 Pharmaceutical composition for treating or preventing degenerative and inflammatory diseases NEUROTECH PHARMACEUTICALS CO., LTD (KR) 2013-06-04 US claimed
US-20120040939-A1 MEDICINAL USE OF 5-BENZYLAMINOSALICYLIC ACID DERIVATIVE OR ITS SALT NEUROTECH PHARMACEUTICALS CO., LTD. (KR) 2012-02-16 US claimed
US-20090281181-A1 Pharmaceutical Composition for Treating or Preventing Degenerative and Inflammatory Diseases GNT PHARMA CO., LTD. (KR) 2009-11-12 US claimed
EP-2004164-A1 PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING DEGENERATIVE AND INFLAMMATORY DISEASES Neurotech Co., Ltd. (KR) 2008-12-24 EP claimed
WO-2007119973-A1 PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING DEGENERATIVE AND INFLAMMATORY DISEASES NEUROTECH CO., LTD. (KR) 2007-10-25 WO claimed
EP-3902536-B1 COMPOSITIONS COMPRISING 5-BENZYLAMINOSALICYLIC ACID COMPOUNDS FOR USE IN TREATING NEURODEGENERATIVE DISORDERS IN A COMPANION ANIMAL GNT PHARMA CO LTD (KR) 2025-09-03 EP disclosed
US-20250255844-A1 COMPOSITIONS AND METHODS FOR TREATING PULMONARY DISORDERS GNT PHARMA CO., LTD. (KR) 2025-08-14 US disclosed
US-20070298129-A1 Compounds and compositions for treating neuronal death or neurological dysfunction NEUROTECH PHARMACEUTICALS CO., LTD. (KR) 2007-12-27 US disclosed
WO-2007119973-A1 PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING DEGENERATIVE AND INFLAMMATORY DISEASES NEUROTECH CO., LTD. (KR) 2007-10-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230233503-A1 COMPOSITIONS AND METHODS FOR TREATING PULMONARY DISORDERS HAO2, ACOX1, HAO1 NOX4 195/4885MCL1 4750/4885BCL2A1 3247/4885
US-20220241231-A1 COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISORDERS PRNP, PSEN1, GRIK5 NOX4 4612/4885MCL1 4125/4885BCL2A1 3008/4885
US-20250255844-A1 COMPOSITIONS AND METHODS FOR TREATING PULMONARY DISORDERS HAO2, ACOX1, HAO1 NOX4 195/4885MCL1 4750/4885BCL2A1 3247/4885
US-20070298129-A1 Compounds and compositions for treating neuronal death or neurological dysfunction BCL2, BAX, SMN1; SMN2 NOX4 2363/4885MCL1 254/4885BCL2A1 24/4885
US-20120040939-A1 MEDICINAL USE OF 5-BENZYLAMINOSALICYLIC ACID DERIVATIVE OR ITS SALT HTR5A, HTR6, MC5R NOX4 1222/4885MCL1 4742/4885BCL2A1 2970/4885
US-20090281181-A1 Pharmaceutical Composition for Treating or Preventing Degenerative and Inflammatory Diseases ALOX12, ALOX15, ALOX15B NOX4 1202/4885MCL1 3218/4885BCL2A1 1195/4885
US-20130316988-A1 Pharmaceutical Composition for Treating or Preventing Degenerative and Inflammatory Diseases ALOX12, ALOX15, ALOX15B NOX4 1202/4885MCL1 3218/4885BCL2A1 1195/4885
US-20200206172-A1 COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISORDERS PRNP, PSEN1, GRIK5 NOX4 4612/4885MCL1 4125/4885BCL2A1 3008/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.